Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

• 年次報告書（10-K）

  事業内容、財務実績、リスクをまとめた年次の概要。

  提出日: 2026-02-19

  書類を見る

• 四半期報告書（10-Q）

  直近3か月間の業績に関する最新情報。

  提出日: 2026-07-30

  書類を見る

• 臨時報告書（8-K）

  経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

  提出日: 2026-08-12

  書類を見る

• 5/6/2026NEUTRAL
  Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call

  Madrigal Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. While the transcript is available, the provided snippet does not contain specific financial results, forward-looking statements, or significant operational updates that would directly impact the company's stock valuation. Investors seeking to assess the company's performance and outlook should refer to the full earnings report and call transcript for detailed financial figures, management commentary on key business drivers, and any guidance provided for future periods. Without this detailed information, a definitive market impact cannot be determined.

• 3/17/2026POSITIVE
  This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally

  Madrigal Pharmaceuticals, a clinical-stage biotech focused on NASH, obesity, and metabolic diseases, has seen its stock surge by an astonishing 1,300%. This remarkable rally has been further bolstered by a significant $181 million investment, underscoring strong investor confidence in the company's therapeutic pipeline. The substantial capital infusion is expected to accelerate clinical development and research efforts, potentially bringing its innovative small-molecule therapies closer to market approval. For investors, this dual validation of strong market performance and external financial backing signals robust growth prospects.

• 2/23/2026NEUTRAL
  Madrigal (MDGL) Q4 2025 Earnings Call Transcript

  Madrigal Pharmaceuticals has released the transcript of its fourth-quarter 2025 earnings conference call. While the news itself is informational, the document is a crucial resource for investors. Analysts and shareholders can now scrutinize the management's detailed commentary on financial performance, drug pipeline progress, and the strategic outlook for the future. The question-and-answer session will be of particular interest, as it often reveals nuances and details not found in official press releases. The availability of this comprehensive documentation allows for a deeper analysis, but does not in itself provide a directional signal until its contents are fully digested by the market.